FORM OF AMENDMENT NO. 1 TO THE CAPITAL ON DEMANDTM SALES AGREEMENT, DATED JULY 31, 2026, BETWEEN NEUROSENSE THERAPEUTICS LTD. AND JONESTRADING INSTITUTIONAL SERVICES LLC
NeuroSense Therapeutics Ltd.
AMENDMENT NO. 1 TO
***CAPITAL ON DEMANDTM SALES AGREEMENT ***
** **
July 31, 2026
** **
This Amendment No. 1 (“Amendment No. 1”) amends that certain Capital on DemandTM Sales Agreement, dated August 16, 2024 (the “Agreement”), by and between NeuroSense Therapeutics Ltd. (the “Company”) and JonesTrading Institutional Services LLC as agent (the “Agent”). Defined terms used herein and not otherwise defined shall have the meaning assigned to such terms in the Agreement.
WITNESSETH THAT:
WHEREAS, Section 16 of the Agreement permits the Company and the Agent to amend the Agreement; and
WHEREAS, the Company and the Agent now desire to amend the Agreement as provided herein.
NOW, THEREFORE, in consideration of the foregoing premises and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Company and the Agent agree as follows:
…